| 1. |
- Borrebaeck, Carl A K
(författare)
-
Precision diagnostics : moving towards protein biomarker signatures of clinical utility in cancer
- 2017
-
Ingår i: Nature Reviews Cancer. - : Springer Science and Business Media LLC. - 1474-175X .- 1474-1768. ; 17:3, s. 199-204
-
Forskningsöversikt (refereegranskat)abstract
- Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.
|
|
| 2. |
- Brennan, Donal J., et al.
(författare)
-
Antibody-based proteomics : fast-tracking molecular diagnostics in oncology
- 2010
-
Ingår i: Nature Reviews. Cancer. - : Springer Science and Business Media LLC. - 1474-175X .- 1474-1768. ; 10:9, s. 605-617
-
Forskningsöversikt (refereegranskat)abstract
- The effective implementation of personalized cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity reagents in clinical diagnostic and predictive assays suggests that the rapid translation of such approaches is an achievable goal. Furthermore, in combination with, or as alternatives to, genomic and transcriptomic methods for patient stratification, antibody-based proteomics approaches offer the promise of additional insight into cancer disease states. In this Review, we discuss the current status of antibody-based proteomics and its contribution to the development of new assays that are crucial for the realization of individualized cancer therapy.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- De Marzo, AM, et al.
(författare)
-
Inflammation in prostate carcinogenesis
- 2007
-
Ingår i: Nature reviews. Cancer. - : Springer Science and Business Media LLC. - 1474-175X .- 1474-1768. ; 7:4, s. 256-269
-
Tidskriftsartikel (refereegranskat)
|
|
| 7. |
|
|
| 8. |
- Elliott, Kerryn, et al.
(författare)
-
Non-coding driver mutations in human cancer.
- 2021
-
Ingår i: Nature reviews. Cancer. - : Springer Science and Business Media LLC. - 1474-1768 .- 1474-175X. ; 21:8, s. 500-509
-
Forskningsöversikt (refereegranskat)abstract
- Tumour formation involves random mutagenic events and positive evolutionary selection acting on a subset of such events, referred to as driver mutations. A decade of careful surveying of tumour DNA using exome-based analyses has revealed a multitude of protein-coding somatic driver mutations, some of which are clinically actionable. Today, a transition towards whole-genome analysis is well under way, technically enabling the discovery of potential driver mutations occurring outside protein-coding sequences. Mutations are abundant in this vast non-coding space, which is more than 50 times larger than the coding exome, but reliable identification of selection signals in non-coding DNA remains a challenge. In this Review, we discuss recent findings in the field, where the emerging landscape is one in which non-coding driver mutations appear to be relatively infrequent. Nevertheless, we highlight several notable discoveries. We consider possible reasons for the relative absence of non-coding driver events, as well as the difficulties associated with detecting signals of positive selection in non-coding DNA.
|
|
| 9. |
- Hallberg, Bengt, et al.
(författare)
-
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
- 2013
-
Ingår i: Nature Reviews. Cancer. - : Nature Publishing Group. - 1474-175X .- 1474-1768. ; 13:10, s. 685-700
-
Tidskriftsartikel (refereegranskat)abstract
- The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.
|
|
| 10. |
|
|
